Business Wire

CRIANN boosts bandwidth in French research and education network with Adtran FSP 3000

5.11.2024 10:00:00 CET | Business Wire | Press Release

Share

Adtran today announced that the Centre Régional Informatique et d’Applications Numériques de Normandie (CRIANN) is using its FSP 3000 optical transport technology and ALM fiber monitoring platform to boost the capacity and resilience of its research and education network, thanks to the financial support of the Normandy Region. By integrating Adtran’s solution, the Normandy-based supercomputing center and provider of high-performance digital infrastructure is ensuring faster and more reliable connectivity for the region’s scientific and academic institutions. Adtran’s Elite partner Axians also played a key role in the installation and continues to deliver maintenance and support.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104047734/en/

Adtran’s technology is helping CRIANN drive high-speed, secure and ultra-reliable connectivity throughout its research and education network. (Photo: Business Wire)

“Our fiber network promotes innovation and the advancement of scientific knowledge. We support academic institutions in several ways, including by enabling data-intensive simulations and AI research for which high-speed, secure and ultra-reliable connectivity is fundamental,” said Alain Bidaud, CTO of CRIANN. “Harnessing Adtran’s optical transport technology, we’ve boosted capacity across our fiber infrastructure while also rendering our services more resilient. The FSP 3000 enables a seamless transition from our existing transport network. What’s more, its modular architecture radically simplifies the upgrade process so we can augment the solution to efficiently and sustainably meet future demand.”

This major upgrade to CRIANN’s research and education network increases bandwidth across all three of its sites. Featuring Adtran’s FSP 3000 OpenFabric™ 1200, the new solution integrates an open and flexible OTN fabric with DWDM transponder functions that deliver up to 400Gbit/s per wavelength and supports multiple OTN and Ethernet client services from 10Gbit/s to 400Gbit/s on a single card. This enables CRIANN to boost transport capacity and ensures the network can easily scale to meet both current and future demands.

CRIANN has also deployed Adtran’s ALM in-service fiber monitoring platform, which provides rapid, detailed alerts in the event of any fiber disruption. Combined with Adtran’s Mosaic Network Controller and Fiber Director, it offers a sophisticated real-time geographic information system that delivers pinpoint accuracy in locating fiber issues. By empowering CRIANN’s maintenance team with a precise understanding of its fiber infrastructure, the technology helps reduce truck rolls, improves network availability and minimizes operating costs.

“Built on our FSP 3000 platform, CRIANN’s upgraded fiber infrastructure is ideally suited to meet the growing demands of research and education networks for higher capacity and greater reliability,” commented Stuart Broome, GM of EMEA sales at Adtran. “Harnessing our OpenFabric™ 1200 switchponder, the new solution supports Ethernet and OTN services up to 400Gbit/s. This technology simplifies operations and maximizes the potential of CRIANN’s fiber assets. With its new, robust network, CRIANN is empowering Normandy’s academic community to take their research to whole new levels.”

“At Axians, we believe in forging connections that matter, not just with technology but also through relationships. Our partnership with CRIANN and Adtran is a testament to this philosophy. Together, we’re ensuring CRIANN’s research and education network can adapt, evolve and meet future challenges,” noted Bruno Durand, GM of Axians communication and cloud Caen. “This deployment is about providing top-tier opportunities for scientists, teachers and students. By merging technical expertise with our commitment to delivering excellence, we’re ensuring that the region stays at the cutting edge of research and innovation.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by 
ADTRAN Holdings, Inc. 
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104047734/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye